miR-539-5p Regulates Irritable Bowel Syndrome Pathological Processes by Targeting KDM6A
Open Access
- 10 September 2025
- journal article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (1) , 15-25
Abstract
Background/Aims: The chronicity and recurrence of irritable bowel syndrome (IBS) pose significant burdens on patients’ lives, making it urgent to understand its underlying mechanisms. This study intends to investigate the function and regulatory mechanisms of miR 539-5p in IBS and lay the foundation for the creation of more effective therapeutic strategies. Materials and Methods: Rat model of IBS with diarrhea (IBS-D) was established and evaluated by the abdominal withdrawal reflex. The IBS cellular model was established in vitro using lipopolysaccharide (LPS), and real-time quantitative polymerase chain reaction was used to assess the changes in the miR-539-5p expression. Cell counting kit-8 assays, flow cytometry, and enzyme-linked immu nosorbent assay were used to evaluate the effects of different treatments on cell viability, paracellular permeability, apoptosis, and inflammatory responses. Bioinformatics techniques and dual-luciferase reporter gene assays were leveraged to forecast and confirm the interaction between miR-539-5p and the KDM6A gene. Results: In IBS-D rats, miR-539-5p was conspicuously downregulated, and miR-539-5p overexpression could improve the symptoms of rats. Under exposure to LPS, the expression of miR-539-5p was evidently decreased. Upregulating miR-539-5p could significantly mitigate LPS-induced cellular damage, namely inhibiting the apoptosis of intestinal mucosal epithelial cells, promoting cell prolifera tion, reducing paracellular permeability, and suppressing the inflammatory response. KDM6A, as the target gene of miR-539-5p, was remarkably upregulated in IBS-D rats and cells exposed to LPS. KDM6A overexpression counteracts the protective effects mediated by the upregulation of miR-539 5p. Conclusion: miR-539-5p may be involved in regulating the pathological processes of IBS-D by targeting KDM6A. Cite this article as: Li Y, Wang Z, Zhang S, Hua Y, Fan X, Li L. MiR-539-5p regulates irritable bowel syndrome pathological processes by targeting KDM6A. Turk J Gastroenterol. Published online September 10, 2025. doi: 10.5152/tjg.2025.24684.Keywords
This publication has 37 references indexed in Scilit:
- Silencing interleukin 1α underlies a novel inhibitory role of miR‐181c‐5p in alleviating low‐grade inflammation of rats with irritable bowel syndromeJournal of Cellular Biochemistry, 2019
- Clostridium butyricum regulates visceral hypersensitivity of irritable bowel syndrome by inhibiting colonic mucous low grade inflammation through its action on NLRP6Acta Biochimica et Biophysica Sinica, 2018
- miR‐539‐5p inhibits experimental choroidal neovascularization by targeting CXCR7The FASEB Journal, 2018
- Irritable Bowel SyndromePrimary Care: Clinics in Office Practice, 2017
- Pathophysiology of irritable bowel syndromeThe Lancet Gastroenterology & Hepatology, 2016
- miR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn’s diseaseScientific Reports, 2015
- Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1Gut, 2015
- Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndromeExperimental and Molecular Pathology, 2014
- Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicineWorld Journal of Gastroenterology, 2014
- Co-Regulation of Transcellular and Paracellular Leak Across Microvascular Endothelium by Dynamin and RacThe American Journal of Pathology, 2012